These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
794 related articles for article (PubMed ID: 17158693)
1. Treatment of rheumatoid arthritis. Gaffo A; Saag KG; Curtis JR Am J Health Syst Pharm; 2006 Dec; 63(24):2451-65. PubMed ID: 17158693 [TBL] [Abstract][Full Text] [Related]
2. Strategies toward rheumatoid arthritis therapy; the old and the new. Abbasi M; Mousavi MJ; Jamalzehi S; Alimohammadi R; Bezvan MH; Mohammadi H; Aslani S J Cell Physiol; 2019 Jul; 234(7):10018-10031. PubMed ID: 30536757 [TBL] [Abstract][Full Text] [Related]
3. [New drugs and treatment strategies for rheumatoid arthritis]. Fantini F Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798 [TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases. Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082 [TBL] [Abstract][Full Text] [Related]
5. New drugs for the treatment of rheumatoid arthritis. Schuna AA; Megeff C Am J Health Syst Pharm; 2000 Feb; 57(3):225-34. PubMed ID: 10674776 [TBL] [Abstract][Full Text] [Related]
6. Biologic agents in rheumatoid arthritis: an update for managed care professionals. Agarwal SK J Manag Care Pharm; 2011; 17(9 Suppl B):S14-8. PubMed ID: 22073935 [TBL] [Abstract][Full Text] [Related]
7. Advances in the treatment of rheumatoid arthritis: old versus new therapies. Saravanan V; Hamilton J Expert Opin Pharmacother; 2002 Jul; 3(7):845-56. PubMed ID: 12083985 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. Fleischmann R; Iqbal I; Nandeshwar P; Quiceno A Drug Saf; 2002; 25(3):173-97. PubMed ID: 11945114 [TBL] [Abstract][Full Text] [Related]
9. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Smolen JS; Landewé RBM; Bijlsma JWJ; Burmester GR; Dougados M; Kerschbaumer A; McInnes IB; Sepriano A; van Vollenhoven RF; de Wit M; Aletaha D; Aringer M; Askling J; Balsa A; Boers M; den Broeder AA; Buch MH; Buttgereit F; Caporali R; Cardiel MH; De Cock D; Codreanu C; Cutolo M; Edwards CJ; van Eijk-Hustings Y; Emery P; Finckh A; Gossec L; Gottenberg JE; Hetland ML; Huizinga TWJ; Koloumas M; Li Z; Mariette X; Müller-Ladner U; Mysler EF; da Silva JAP; Poór G; Pope JE; Rubbert-Roth A; Ruyssen-Witrand A; Saag KG; Strangfeld A; Takeuchi T; Voshaar M; Westhovens R; van der Heijde D Ann Rheum Dis; 2020 Jun; 79(6):685-699. PubMed ID: 31969328 [TBL] [Abstract][Full Text] [Related]
10. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany. Li N; Betts KA; Messali AJ; Skup M; Garg V Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087 [TBL] [Abstract][Full Text] [Related]
11. Perinatal use and discontinuation of disease-modifying anti-rheumatic drugs and biologics in women with rheumatoid arthritis: a cohort study. Rebić N; Sayre EC; Zusman EZ; Amiri N; Baldwin C; De Vera MA Rheumatology (Oxford); 2020 Jul; 59(7):1514-1521. PubMed ID: 31628479 [TBL] [Abstract][Full Text] [Related]
12. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622 [TBL] [Abstract][Full Text] [Related]
13. Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars. Woodworth TG; den Broeder AA Best Pract Res Clin Rheumatol; 2015; 29(4-5):543-9. PubMed ID: 26697765 [TBL] [Abstract][Full Text] [Related]
14. The use of biologic therapies in the treatment of rheumatoid arthritis. Wang D; Li Y; Liu Y; Shi G Curr Pharm Biotechnol; 2014; 15(6):542-8. PubMed ID: 25213363 [TBL] [Abstract][Full Text] [Related]
16. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. Gibbons LJ; Hyrich KL BioDrugs; 2009; 23(2):111-24. PubMed ID: 19489652 [TBL] [Abstract][Full Text] [Related]
17. Therapy of rheumatoid arthritis: new developments and trends. St Clair EW Curr Rheumatol Rep; 1999 Dec; 1(2):149-56. PubMed ID: 11123029 [TBL] [Abstract][Full Text] [Related]
18. Emerging therapeutics for rheumatoid arthritis. Bingham CO Bull NYU Hosp Jt Dis; 2008; 66(3):210-5. PubMed ID: 18937634 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Kerschbaumer A; Sepriano A; Bergstra SA; Smolen JS; van der Heijde D; Caporali R; Edwards CJ; Verschueren P; de Souza S; Pope JE; Takeuchi T; Hyrich KL; Winthrop KL; Aletaha D; Stamm TA; Schoones JW; Landewé RBM Ann Rheum Dis; 2023 Jan; 82(1):95-106. PubMed ID: 36368906 [TBL] [Abstract][Full Text] [Related]
20. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ramiro S; Gaujoux-Viala C; Nam JL; Smolen JS; Buch M; Gossec L; van der Heijde D; Winthrop K; Landewé R Ann Rheum Dis; 2014 Mar; 73(3):529-35. PubMed ID: 24401994 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]